Press release
Dementia - Pipeline Review, H2 2017
Dementia - Pipeline Review, H2 2017
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H2 2017, provides an overview of the Dementia (Central Nervous System) pipeline landscape.
Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.
To Enquire about this Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41690
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 11, 19, 1, 39, 10 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 11 and 3 molecules, respectively.
Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)
To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/dementia-pipeline-review-h2-2017
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.
Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston,
MA 02110
US
Phone +1 (617) 398-1947
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dementia - Pipeline Review, H2 2017 here
News-ID: 786106 • Views: …
More Releases from ReportsWorldwide
World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence…
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports.
Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors.
Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that…
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports.
This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers:
• CommScope/Airvana
• Comba Telecom
• Ericsson
• Huawei Technologies
• Nokia
• SpiderCloud
• ZTE Corporation
This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021.
To view a detailed description and Table of…
More Releases for Dementia
Dementia Care APP Market Is Booming Worldwide 2021-2027 | Dementia Digital Diary …
Global Dementia Care APP market 2020-2026 in-depth study accumulated to supply latest insights concerning acute options. The report contains different predictions associated with Dementia Care APP market size, revenue, production, CAGR, consumption, profit margin, price, and different substantial factors. Whereas accentuation the key driving and Dementia Care APP restraining forces for this market, the report offers trends and developments. It additionally examines the role of the leading…
Dementia screening and prevention – hope or hype?
It is estimated that about 50% of dementia patients do not receive a formal diagnosis. And when the diagnosis is made, it often happens at a time when the disease is well advanced and brain damages are irreversible.
A major reason for this is that systematic dementia screening and prevention programmes are not yet ready for implementation as large-scale public health interventions. A key reason for this is the desire…
Dementia Treatment
Dementia Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025
The global Dementia Drugs and Treatment market is valued at 13900 million US$ in 2018 is expected to reach 26500 million US$ by the end of 2025, growing at a CAGR of 8.4% during 2019-2025.
This report focuses on Dementia Drugs volume and value at global level, regional level and company level. From a global perspective, this…
New App detects dementia risks early
• The App is certified as a Medical Device.
• Early stages are reliably detected, before the brain damage becomes irreversible.
• Sensitivity above 96%, significantly higher than with the established tests (e.g., MMSE 71%).
• Now available for free during pre-launch.
Dementia is a rapidly increasing social problem of a rapidly aging society. Because until today there is no effective therapy for advanced stages of dementia.
Therefore, effective screening tests are needed to detect early stages…
2nd International Conference on Dementia and Dementia Care
Breakthrough in Dementia Research and Care
Event Name: 2nd International Conference on Dementia and Dementia Care (Dementia 2019)
Theme: Breakthrough in Dementia Research and Care
Aim and Scope: Dementia is an umbrella term used to describe a set of symptoms that occur when the brain is affected by disease. There’s currently no cure and no treatment that slows or stops its progression, but there are things you can do to help reduce the…
11th International Conference on Vascular Dementia
Can We Cure Dementia, Vascular Dementia and Alzheimer's disease?
It’s our pleasure to invite all the participants from all over the world to attend the 11th International Conference on Vascular Dementia which is held during February 15-16, 2019 Amsterdam| Netherlands.
Vascular Dementia conference will assemble illustrious speakers, Researchers, Nobel laureates, Neurologists, and Neuroscience researchers from both academic and health care professionals will join this event to discuss their views and research. The…
